2013
Global Resting-State Functional Magnetic Resonance Imaging Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-Compulsive Disorder
Anticevic A, Hu S, Zhang S, Savic A, Billingslea E, Wasylink S, Repovs G, Cole MW, Bednarski S, Krystal JH, Bloch MH, Li CS, Pittenger C. Global Resting-State Functional Magnetic Resonance Imaging Analysis Identifies Frontal Cortex, Striatal, and Cerebellar Dysconnectivity in Obsessive-Compulsive Disorder. Biological Psychiatry 2013, 75: 595-605. PMID: 24314349, PMCID: PMC3969771, DOI: 10.1016/j.biopsych.2013.10.021.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAgedBrainBrain MappingCerebellumCorpus StriatumFemaleFrontal LobeHumansMagnetic Resonance ImagingMaleMiddle AgedNeural PathwaysObsessive-Compulsive DisorderRestYoung AdultConceptsObsessive-compulsive disorderPrefrontal cortexResting-state functional connectivity dataStriatum/nucleus accumbensVentral striatum/nucleus accumbensResting-state functional connectivity studiesVentral anterior cingulate cortexCortico-striatal circuitsMagnetic Resonance Imaging AnalysisAnterior cingulate cortexFunctional connectivity studiesBasal gangliaControl subjectsFunctional connectivity dataAnterior thalamusRight putamenFrontal cortexNucleus accumbensDorsal striatumCerebellar cortexAbnormal neural connectivityCerebellar dysconnectivityCingulate cortexWhole brainFunctional magnetic resonance imaging (fMRI) analysis
2012
Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder
Bloch MH, Wasylink S, Landeros-Weisenberger A, Panza KE, Billingslea E, Leckman JF, Krystal JH, Bhagwagar Z, Sanacora G, Pittenger C. Effects of Ketamine in Treatment-Refractory Obsessive-Compulsive Disorder. Biological Psychiatry 2012, 72: 964-970. PMID: 22784486, PMCID: PMC3667652, DOI: 10.1016/j.biopsych.2012.05.028.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderKetamine infusionDepression symptomsLow-dose ketamine infusionTreatment-refractory obsessive-compulsive disorderOCD symptomsPathogenesis of OCDIncomplete symptom reliefTreatment-Refractory ObsessiveOpen-label trialRapid antidepressant effectsAspartate glutamate receptorsEffects of ketaminePotent noncompetitive antagonistGlutamate abnormalitiesAntidepressant effectsAntidepressant responseSymptom reliefKetamine effectsComorbid depressionAcute effectsGlutamate receptorsDepressive symptomsNoncompetitive antagonistInfusion
2009
Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder
Landeros-Weisenberger A, Bloch MH, Kelmendi B, Wegner R, Nudel J, Dombrowski P, Pittenger C, Krystal JH, Goodman WK, Leckman JF, Coric V. Dimensional predictors of response to SRI pharmacotherapy in obsessive–compulsive disorder. Journal Of Affective Disorders 2009, 121: 175-179. PMID: 19577308, PMCID: PMC3974618, DOI: 10.1016/j.jad.2009.06.010.Peer-Reviewed Original ResearchConceptsObsessive-compulsive disorderSRI responseSymptom dimensionsOpen-label continuation phaseClinical Global Improvement ScaleGlobal Improvement ScaleCentral serotonin systemInitial positive responseYale-Brown ObsessiveContinuation phaseMinor symptomsOrdinal logistic regressionClinical trialsSerotonin systemTreatment responseSame patientImprovement ScaleSRI treatmentPatientsSignificant associationLogistic regressionCompulsive ScaleOCD patientsOCD subjectsSymptoms
2006
Beneficial Effects of the Glutamate-modulating Agent Riluzole on Disordered Eating and Pathological Skin-picking Behaviors
Sasso DA, Kalanithi PS, Trueblood KV, Pittenger C, Kelmendi B, Wayslink S, Malison RT, Krystal JH, Coric V. Beneficial Effects of the Glutamate-modulating Agent Riluzole on Disordered Eating and Pathological Skin-picking Behaviors. Journal Of Clinical Psychopharmacology 2006, 26: 685-687. PMID: 17110840, DOI: 10.1097/01.jcp.0000245567.29531.d6.Peer-Reviewed Original ResearchGlutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder
Pittenger C, Krystal JH, Coric V. Glutamate-modulating drugs as novel pharmacotherapeutic agents in the treatment of obsessive-compulsive disorder. Neurotherapeutics 2006, 3: 69-81. PMID: 16490414, PMCID: PMC3593363, DOI: 10.1016/j.nurx.2005.12.006.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive Agents, TricyclicBrainExcitatory Amino Acid AntagonistsGlutamic AcidHumansMagnetic Resonance ImagingObsessive-Compulsive DisorderConceptsGlutamate modulating agentsObsessive-compulsive disorderTreatment of OCDRecent magnetic resonance spectroscopy (MRS) studyTreatment-resistant obsessive-compulsive disorderModulating agentsGlutamate-modulating drugsThalamo-cortical circuitrySerotonin reuptake inhibitorsElevated glutamate levelsCurrent treatment strategiesMagnetic resonance spectroscopy studyCommon psychiatric disordersNovel pharmacotherapeutic agentsAmyotrophic lateral sclerosisNovel therapeutic interventionsFunctional neuroimaging studiesGlutamate hyperactivityComplete remissionReuptake inhibitorsGlutamatergic activityMetabolic hyperactivitySignificant morbidityCase reportCortico-striato
2005
N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder
Lafleur DL, Pittenger C, Kelmendi B, Gardner T, Wasylink S, Malison RT, Sanacora G, Krystal JH, Coric V. N-acetylcysteine augmentation in serotonin reuptake inhibitor refractory obsessive-compulsive disorder. Psychopharmacology 2005, 184: 254-256. PMID: 16374600, DOI: 10.1007/s00213-005-0246-6.Peer-Reviewed Original ResearchMeSH KeywordsAcetylcysteineDrug ResistanceDrug SynergismFemaleFluvoxamineHumansMiddle AgedObsessive-Compulsive DisorderPsychiatric Status Rating ScalesSelective Serotonin Reuptake InhibitorsConceptsRefractory obsessive-compulsive disorderObsessive-compulsive disorderN-acetylcysteineGlutamatergic neurotransmissionUse of NACYale-Brown Obsessive Compulsive Scale scoresSerotonin reuptake inhibitorsEfficacy of augmentationRecent clinical reportsTreatment of OCDCompulsive Scale scoresNAC augmentationGlutamatergic dysfunctionReuptake inhibitorsLabel usePsychiatric disordersClinical reportsScale scoreModulating agentsDisordersSingle casePatientsFluvoxamineNeurotransmissionOCD symptomsRiluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial
Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH. Riluzole Augmentation in Treatment-Resistant Obsessive–Compulsive Disorder: An Open-Label Trial. Biological Psychiatry 2005, 58: 424-428. PMID: 15993857, DOI: 10.1016/j.biopsych.2005.04.043.Peer-Reviewed Original ResearchMeSH KeywordsAdultDrug ResistanceExcitatory Amino Acid AntagonistsFemaleHumansMaleMiddle AgedObsessive-Compulsive DisorderRiluzoleTime FactorsTreatment OutcomeConceptsTreatment-resistant obsessive-compulsive disorderObsessive-compulsive disorderY-BOCS scoresYale-Brown Obsessive Compulsive ScaleTreatment-resistant OCD patientsAddition of riluzolePractical clinical benefitOpen-label trialGlutamate-modulating agentsSerious adverse effectsHamilton Depression InventoryAnxiety Inventory scoresObsessive Compulsive ScaleMost patientsStandard therapyGlutamatergic dysfunctionAugmentation therapyClinical benefitPrimary diagnosisStandard treatmentCorticostriatal pathwayTreatment respondersRiluzolePatientsDepression Inventory
2003
Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder
Coric V, Milanovic S, Wasylink S, Patel P, Malison R, Krystal JH. Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder. Psychopharmacology 2003, 167: 219-220. PMID: 12658528, DOI: 10.1007/s00213-003-1396-z.Peer-Reviewed Original ResearchMeSH KeywordsAntidepressive AgentsDepressive Disorder, MajorHumansMaleMiddle AgedObsessive-Compulsive DisorderRiluzoleConceptsMajor depressive disorder
1990
Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine
Goodman WK, Price LH, Delgado PL, Palumbo J, Krystal JH, Nagy LM, Rasmussen SA, Heninger GR, Charney DS. Specificity of Serotonin Reuptake Inhibitors in the Treatment of Obsessive-Compulsive Disorder: Comparison of Fluvoxamine and Desipramine. JAMA Psychiatry 1990, 47: 577-585. PMID: 2112374, DOI: 10.1001/archpsyc.1990.01810180077011.Peer-Reviewed Original ResearchConceptsSerotonin reuptake inhibitorsObsessive-compulsive disorderReuptake inhibitorsComparison of fluvoxamineSerotonin receptor functionDouble-blind fashionGlobal response rateWeeks of treatmentBaseline depressive symptomsYale-Brown Obsessive Compulsive ScaleMechanism of actionObsessive Compulsive ScaleReuptake inhibitionDopaminergic functionPrincipal diagnosisDepressive symptomsResponse rateFluvoxamineDesipramineReceptor functionObsessive-compulsive symptomsDesipramine hydrochlorideCompulsive ScaleSymptomsFluvoxamine maleateNeuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder
McDougle CJ, Goodman WK, Price LH, Delgado PL, Krystal JH, Charney DS, Heninger GR. Neuroleptic addition in fluvoxamine-refractory obsessive-compulsive disorder. American Journal Of Psychiatry 1990, 147: 652-654. PMID: 1970224, DOI: 10.1176/ajp.147.5.652.Peer-Reviewed Original Research